Mark Rothera - Mar 12, 2024 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: President and CEO, Director
Signature: Daniel Chevallard, as Attorney-in-Fact
Stock symbol: VIRX
Transactions as of: Mar 12, 2024
Transactions value $: $0
Form type: 4
Date filed: 3/13/2024, 08:36 PM
Previous filing: Dec 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+475K		$0.00	475K	Mar 12, 2024	Common Stock	475K	$0.99	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2024.

Content

1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2024.